Research & Development
Investigational Therapeutic for Episodic Cardiovascular Conditions
We are investigating etripamil as the first self-administered therapy for the rapid termination of episodic cardiovascular conditions wherever and whenever they occur.
Calcium channel blockers, usually administered intravenously in the emergency department, have been approved for decades for the treatment of PSVT or other cardiac conditions. Etripamil’s combination of convenient delivery, rapid onset, and short duration of action has the potential to shift the current treatment paradigm away from the burdensome and costly emergency department or hospital setting.
Completed Clinical Trials
We completed a Phase 1 clinical trial in healthy adults which supported the selection of four doses of intranasal etripamil for a Phase 2 clinical trial to evaluate the effects of those four doses among patients living with PSVT.
Phase 2 results, published in the Journal of the American College of Cardiology, show that 87% of PSVT episodes were stopped within 15 minutes of using etripamil at the dose selected for Phase 3 versus 35% for placebo.
Current and Future Clinical Trials
We are actively recruiting patients for a Phase 3 clinical trial, NODE-301, to assess the safety and efficacy of etripamil for the treatment of PSVT in the outpatient setting. Patients who experience a PSVT episode in NODE-301 have the opportunity to enroll in NODE-302, an open label extension trial, capturing further safety information on etripamil.
We continue to plan other clinical trials testing etripamil in PSVT. We are also planning to initiate Phase 2 clinical trials in atrial fibrillation, another rapid heartbeat condition, and angina, to establish proof-of-concept for the broader use of etripamil.